ADVERTISEMENT
Psychedelics Business Briefs: Numinus, Delix, Irwin Naturals
Numinus Adds Clinical Research Site in Phoenix
Numinus Wellness announced this week that it has added a clinical research site in Phoenix, Arizona. The facility, the company’s third clinical trial research site in the US and fifth overall, will focus on advancing psychedelic science through Cedar Clinical Research.
The new research site is located within an existing leased facility, next to one of Numinus’ wellness clinics. The site’s first clinical trial is expected to begin in early March.
As of its most recently reported financial quarter, ended November 30, 2022, Cedar Clinical Research managed 14 clinical trials for third-party biotech and psychedelics sector companies.
Delix Announces Partnerships, Personnel Move
Delix Therapeutics, a developer of novel neuroplasticity-promoting therapeutics for psychiatric and neurological conditions, recently announced a collaboration with 2 partner organizations in an effort to expedite the company’s drug development pipeline.
Delix has partnered with Cellectricon, a Sweden-based collaborative services provider that advances drug discovery through in vitro research initiatives. Delix is partnering with Cellectricon to create assessments to measure the structural and functional plasticity effect of Delix’s psychoplastogen compounds. Second, Delix has partnered with Expressive Neuroscience to accelerate decision making in advancing Delix’s library of more than 1400 compounds.
In its news release announcing the 2 partnerships, Delix also confirmed the addition of Alison Mungenast, PhD, as senior director of neuroplasticity. Dr Mungenast joins Delix after most recently managing the central nervous system cell therapy group at Sana Biotechnology.
Irwin Naturals Completes Acquisition of Serenity Health
Irwin Naturals announced on Tuesday that it has completed its acquisition of Serenity Health, a ketamine clinic in Louisville, Kentucky. The deal was initially announced in November 2022 and completed on February 16.
Irwin Naturals said in a news release that it projects its acquisition of Serenity Health will add $3 million in EBITDA and that the deal is a key step in a strategic plan to broaden its network of Irwin Naturals Emergence psychedelic mental health clinics. With its acquisition of Serenity Health, the company’s portfolio includes 22 clinics overall.
References
